secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001809519-25-000021
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx names Christopher McGinnis as CFO, effective Feb 4, 2025
---------------------------------------------------------------

- McGinnis was CEO of Citizens Rx; succeeds Romin Nabiey (interim CFO), who remains CAO.
- Base salary of $500,000; eligible for annual cash bonus targeted at 100% of base salary.
- One-time signing bonus of $250,000; must remain employed through first anniversary or repay pro-rata.
- Equity awards totaling $7M: $3.5M RSU and $3.5M option; vest 25% on Feb 15, 2026 then quarterly over 4 years.
- McGinnis becomes a Tier 1 participant in the Executive Severance Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000021/0001809519-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000021/gdrx-20250204.htm
  HTML page:      https://secwatch.observer/filing/0001809519-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer